Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Anika Therapeutics Inc. - Common Stock
(NQ:
ANIK
)
16.17
+1.02 (+6.73%)
Official Closing Price
Updated: 4:15 PM EDT, Jul 29, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
124,875
Open
17.23
Bid (Size)
15.28 (100)
Ask (Size)
18.00 (100)
Prev. Close
15.15
Today's Range
15.80 - 17.75
52wk Range
7.870 - 16.49
Shares Outstanding
14,828,456
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Anika Therapeutics Q2 Earnings Call Highlights
↗
Today 10:04 EDT
Anika Therapeutics (NASDAQ:ANIK) reported higher second-quarter revenue, expanded gross margin and its strongest adjusted EBITDA performance since 2020, as international commercial growth and...
Via
MarketBeat
Topics
Earnings
Anika Therapeutics (NASDAQ:ANIK) Soars on Q2 Earnings Beat, Revenue and EPS Top Estimates
↗
Today 8:22 EDT
Via
Chartmill
Topics
Earnings
Performance
YTD
+72.9%
+72.9%
1 Month
+7.7%
+7.7%
3 Month
+6.0%
+6.0%
6 Month
+76.7%
+76.7%
1 Year
+42.7%
+42.7%
More News
Read More
Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026
July 15, 2026
From
Anika Therapeutics Inc.
Via
GlobeNewswire
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 05, 2026
From
Anika Therapeutics Inc.
Via
GlobeNewswire
Anika Therapeutics Inc (NASDAQ:ANIK) Soars on Q1 Earnings and Revenue Beat
↗
April 29, 2026
Via
Chartmill
ANIKA THERAPEUTICS INC (NASDAQ:ANIK) Delivers Decisive Q4 2025 Earnings Beat, Sparking Share Rally
↗
February 26, 2026
Via
Chartmill
Topics
Earnings
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues
April 30, 2026
From
TELA Bio, Inc.
Via
GlobeNewswire
Anika (ANIK) Q1 2026 Earnings Transcript
↗
April 29, 2026
Via
The Motley Fool
Anika (ANIK) Q2 2025 Earnings Call Transcript
↗
April 21, 2026
Via
The Motley Fool
Topics
Earnings
Anika (ANIK) Q4 2025 Earnings Call Transcript
↗
April 21, 2026
Via
The Motley Fool
Topics
Earnings
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
April 16, 2026
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026
April 15, 2026
From
Anika Therapeutics Inc.
Via
GlobeNewswire
Organogenesis Clears Major FDA Hurdle: Path to First Non-Surgical Biologic for Knee Osteoarthritis Widens
April 13, 2026
Via
MarketMinute
Telix Strengthens Board with Additional Director Appointments
April 08, 2026
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2026
From
Anika Therapeutics Inc.
Via
GlobeNewswire
Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference
February 18, 2026
From
Anika Therapeutics Inc.
Via
GlobeNewswire
Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026
February 12, 2026
From
Anika Therapeutics Inc.
Via
GlobeNewswire
ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Anika Therapeutics Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Anika Stockholders
January 26, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
ANIK INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Anika Therapeutics, Inc.
January 23, 2026
From
Kirby McInerney LLP
Via
Business Wire
Anika Therapeutics Announces Leadership Transition
January 08, 2026
From
Anika Therapeutics Inc.
Via
GlobeNewswire
ANIK Investigation: Investors Encouraged to Contact Kirby McInerney LLP
December 30, 2025
From
Kirby McInerney LLP
Via
Business Wire
Anika Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors ANIK
December 05, 2025
From
Kirby McInerney LLP
Via
GlobeNewswire
Anika (ANIK) Q3 2025 Earnings Call Transcript
↗
November 05, 2025
Via
The Motley Fool
Topics
Earnings
Anika Therapeutics Inc (NASDAQ:ANIK) Reports Q3 2025 Earnings Beat and Positive Regulatory Milestone
↗
November 05, 2025
Via
Chartmill
Topics
Earnings
Anika Therapeutics Reports Filing of Final PMA Module for Hyalofast® Cartilage Repair Scaffold and Data from U.S. Pivotal FastTRACK Phase III Study
November 05, 2025
From
Anika Therapeutics Inc.
Via
GlobeNewswire
Frequently Asked Questions
Is Anika Therapeutics Inc. - Common Stock publicly traded?
Yes, Anika Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Anika Therapeutics Inc. - Common Stock trade on?
Anika Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Anika Therapeutics Inc. - Common Stock?
The ticker symbol for Anika Therapeutics Inc. - Common Stock is ANIK on the Nasdaq Stock Market
What is the current price of Anika Therapeutics Inc. - Common Stock?
The current price of Anika Therapeutics Inc. - Common Stock is 16.17
When was Anika Therapeutics Inc. - Common Stock last traded?
The last trade of Anika Therapeutics Inc. - Common Stock was at 07/29/26 04:15 PM ET
What is the market capitalization of Anika Therapeutics Inc. - Common Stock?
The market capitalization of Anika Therapeutics Inc. - Common Stock is 239.78M
How many shares of Anika Therapeutics Inc. - Common Stock are outstanding?
Anika Therapeutics Inc. - Common Stock has 240M shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
